SESSION TITLE: Treatment of IPF
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Monday, October 24, 2016 at 07:30 AM - 08:30 AM
PURPOSE: In a pooled analysis of data from the two replicate Phase III INPULSIS trials in patients with idiopathic pulmonary fibrosis (IPF), nintedanib significantly reduced the risk of disease progression over 52 weeks, defined as an absolute decline in forced vital capacity (FVC) of ≥5% predicted or death, or ≥10% predicted or death, versus placebo. We investigated whether nintedanib had the same effect on disease progression in subgroups defined by composite physiologic index (CPI) at baseline, a measure that reflects the extent of pulmonary fibrosis on computed tomography (i.e. a higher score is worse) and is associated with prognosis.